76P Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): Pooled analysis of phase III clinical trials
| Autor: | Luke, J.J., Long, G.V., Robert, C., Carlino, M.S., Choueiri, T.K., Haas, N.B., O'Brien, M.E.R., Paz-Ares, L., Peters, S., Powles, T.B., Leiby, M.A., Lin, J., Zhao, Y., Krepler, C., Perini, R.F., Pietanza, M.C., Samkari, A., Gruber, T., Ibrahim, N., Eggermont, A.M.M. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2022 16 Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|